Skip to main content

Baxter International Value Stock - Dividend - Research Selection

Baxter international

ISIN: US0718131099 , WKN: 853815

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Baxter International Inc. provides a portfolio of healthcare products. The company operates through North and South America; Europe, Middle East and Africa; and Asia-Pacific segments. It offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; renal replacement therapies and other organ support therapies focused in the intensive care unit; sterile intravenous (IV) solutions, IV therapies, infusion pumps, administration sets, and drug reconstitution devices; and parenteral nutrition therapies. The company also provides biological products and medical devices, and surgical hemostat and sealant products used in surgical procedures for hemostasis, tissue sealing, and adhesion prevention; premixed and oncology drug platforms, inhaled anesthesia and critical care products, and pharmacy compounding services; and generic injectable pharmaceuticals. Its products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors\' offices, and by patients at home under physician supervision. The company sells its products through direct sales force, independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic molecules. Baxter International Inc. was founded in 1931 and is headquartered in Deerfield, Illinois.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


The Bottom Fishing Club - Embecta: Excellent Turnaround Prospect In Defensive Medical Products

2026-08-24
Embecta (EMBC) looks like a deep value buy: P/E under 3x, 50%+ FCF yield, insider buying and rebound setup.

3 Unpopular Stocks That Fall Short

2026-08-21
Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad things about a company because it can jeopardize their other revenue-generating business lines like M&A advisory.

Baxter hires new CFO with visa contingency

2026-08-20
John Rogers is expected to take the Deerfield, Illinois-based medical device company’s CFO seat on Oct. 1.

Baxter hires CFO from Smith & Nephew

2026-08-20
John Rogers, who has experience leading change at companies, is expected to help Baxter’s turnaround gain traction. He joins Baxter after the company sold two business units.

Baxter Appoints John Rogers Chief Financial Officer

2026-08-19
DEERFIELD, Ill., August 19, 2026--Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced it has appointed John Rogers as executive vice president and chief financial officer (CFO), reporting to Baxter president and chief executive officer (CEO), Andrew Hider, effective Oct. 1, 2026.

Baxter Announces Pricing for Its Upsized Cash Tender Offers

2026-08-18
DEERFIELD, Ill., August 18, 2026--Baxter International Inc. (NYSE:BAX) ("Baxter" or the "Company") today announced the pricing terms for its previously announced cash tender offers (each, an "Offer" and collectively, the "Offers") of the Company's validly tendered (and not validly withdrawn) notes set forth below (the "Notes") using a "waterfall" methodology under which the Company will accept the Notes in order of their respective acceptance priority levels noted in the table below (the "Accept

COO Stock Surges 22% in Past Three Months: What's Driving the Uptrend?

2026-08-18
Cooper Companies' 22% three-month surge reflects contact lens share gains, MiSight growth and a recovering fertility business.

Baxter Announces Early Tender Results and Upsizing of Previously Announced Cash Tender Offers

2026-08-18
DEERFIELD, Ill., August 18, 2026--Baxter International Inc. (NYSE:BAX) ("Baxter" or the "Company") today announced the early results of its previously announced cash tender offers (each, an "Offer" and collectively, the "Offers") for its validly tendered (and not validly withdrawn) notes set forth below (collectively, the "Notes"). The Offers are being made pursuant to an Offer to Purchase, dated Aug. 4, 2026 (as it may be amended or supplemented from time to time, the "Offer to Purchase"), whic

Baxter’s interim CFO leaves for Cardinal Health

2026-08-18
Anita Zielinski will join Cardinal Health in November as its new chief accounting officer.

3 Stocks Under $50 with Questionable Fundamentals

2026-08-16
The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead. They also usually carry less risk than penny stocks, though they’re not immune to volatility as many lack the scale advantages of their larger peers.